AC Immune receives milestone payment for crenezumab moving into phase III clinical development in Alzheimer's disease | AC Immune SA

AC Immune receives milestone payment for crenezumab moving into phase III clinical development in Alzheimer's disease

Jul 22, 2015

English 148.5 KB

Français 151 KB

Deutsch 152.6 KB

Phase III clinical program to evaluate crenezumab in people with prodromal-to-mild Alzheimer's disease
AC Immune receives milestone under 2006 collaboration with Genentech